Article
High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Oncology reports - 1 Feb 2017
Fujiyoshi Kenji, Yamamoto Gou, Takahashi Akemi, Arai Yoshiko, Yamada Mina, Kakuta Miho, Yamaguchi Kensei, Akagi Yoshito, Nishimura Yoji, Sakamoto Hirohiko, Akagi Kiwamu
Abstract excerpt
Genetic testing is needed for the treatment of colorectal cancer (CRC), especially molecular-targeted therapy. The effects of anti-EGFR therapy and prognosis are affected by the presence of KRAS mutations. However, whether primary CRC or metastatic tissues are appropriate in the analysis is still unclear. In the present study, we assessed the concordance of KRAS/BRAF mutation status and microsatellite instability...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.